Catalyst Pharmaceuticals' $31.50 Share Deal Faces Fairness Probe
Catalyst Pharmaceuticals is being sold to Angelini Pharma at $31.50 per share cash. Shareholder rights law firm Halper Sadeh LLC is investigating the deal's fairness and may seek additional consideration or remedies on behalf of investors.
1. Proposed $31.50 Cash Acquisition of Catalyst Pharmaceuticals
Catalyst Pharmaceuticals agreed to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, representing a significant premium over recent trading levels. The transaction remains subject to regulatory approvals and a shareholder vote before closing.
2. Shareholder Rights Investigation Initiated
Halper Sadeh LLC has launched an investigation into potential federal securities law violations and breaches of fiduciary duty related to the sale. The firm offers representation on a contingent fee basis and is evaluating whether the transaction terms disadvantage ordinary shareholders.
3. Possible Remedies and Deal Impact
On behalf of investors, the law firm may seek increased consideration, supplemental disclosures, or other relief to enhance shareholder value. Any successful challenge could lead to revised deal terms or higher payouts for Catalyst Pharmaceuticals’ shareholders.